Table 3

Cox proportional hazard regressions for estimation of adjusted HRs on SLE

VariableHR (95% CI)
1:20 age-matched and sex-matched population1:2 PSM population
Model 1: ITP exposure aloneModel 2: ITP exposure +demographic variablesModel 3: model 2+medical utilisation and comorbidities at baselineModel 4: conditional cox model with ITP exposure alone
ITP (ref: non-ITP)28.7 (17.3 to 47.6)28.5 (17.2 to 47.3)25.1 (13.7 to 46.0)17.4 (5.28 to 57.4)
Sex (ref: male)
 Female20.7 (5.01 to 84.8)20.5 (4.94 to 84.9)
Age (ref: 30–45)
 <301.19 (0.63 to 2.24)1.20 (0.62 to 2.32)
 45–650.58 (0.28 to 1.21)0.56 (0.25 to 1.25)
 ≥650.44 (0.18 to 1.07)0.42 (0.15 to 1.21)
Urbanisation (ref: Urban)
 Suburban1.09 (0.63 to 1.88)1.13 (0.65 to 1.97)
 Rural0.68 (0.24 to 1.91)0.71 (0.25 to 2.01)
Low incomeCannot estimateCannot estimate
Length of hospital stays* (ref: 0 day)
 1–6 days1.35 (0.69 to 2.65)
 ≥7 days0.91 (0.35 to 2.35)
Comorbidity†
 Rheumatoid arthritis2.02 (0.39 to 10.40)
 Sjogren syndrome6.02 (1.33 to 27.34)
 Systemic sclerosisCannot estimate
 Vasculitis4.24 (0.84 to 21.5)
 Hypertension1.36 (0.56 to 3.33)
 Diabetes mellitus0.75 (0.24 to 2.38)
 Hyperlipidaemia0.41 (0.09 to 1.79)
 Coronary artery disease0.23 (0.03 to 1.79)
 Osteoporosis1.20 (0.34 to 4.21)
 Cerebral vascular accident1.93 (0.51 to 7.26)
 Asthma1.41 (0.43 to 4.68)
 Chronic obstructive pulmonary disease1.06 (0.40 to 2.77)
 Chronic kidney diseaseCannot estimate
 Chronic liver diseases1.55 (0.71 to 3.39)
 Hyperthyroidism1.93 (0.58 to 6.40)
 ThyroiditisCannot estimate
 PancreatitisCannot estimate
 Affective psychosisCannot estimate
 Ankylosing spondylitisCannot estimate
 IBD0.70 (0.09 to 5.24)
 HIVCannot estimate
 APSCannot estimate
  • *Length of hospital stay was identified within 2 years before index date.

  • †Comorbidity was identified within 1 year before index date.

  • APS, antiphospholipid antibody syndrome; IBD, inflammatory bowel disease; ITP, idiopathic thrombocytopenic purpura; PSM, propensity score matching; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus.